Abstract

Treatment of pancreatic cancer by inhibiting the aberrant activation of the survival signaling pathways has received considerable attention. We investigated the probable action of DHA on the suppression of cell proliferation in human pancreatic ductal adenocarcinoma (PDAC) cells. Our results demonstrated that DHA dose-dependently inhibited cell proliferation through an induction of cell cycle arrest in human PDAC cells. DHA suppressed the expression of phosphorylated-Rb (p-Rb), cyclin D1, cyclin E, cyclin A, E2F1 and c-Myc proteins. Blocking the activation of STAT3 signaling pathway led to an inactivation of CAMKII and increased phosphorylation of c-Myc (T58) protein accompanied with decreased expression of c-Myc protein. Treatment of DHA effectively inhibited cell survival through decreased phosphorylation levels of EGFR, STAT3 and CAMKII proteins. The mechanisms of action were associated with increased phosphorylation levels of c-Myc (T58) and instability of c-Myc proteins. DHA inhibited cell survival through an increased GSSG/GSH ratio and oxidative stress level in HPAF-II cells. DHA induced cell apoptosis through increased expression of Bax, c-caspase 3 and c-PARP proteins in HPAF-II cells. Moreover, treatment of DHA significantly inhibited nucleotide synthesis. In conclusion, DHA might significantly suppress the proliferation of PDAC cells and therefore have potential as an anti-cancer therapeutic agent.

Highlights

  • Our results showed that high concentration of glucose (HG) (25 mM) significantly induces the proliferation of human pancreatic ductal adenocarcinoma (PDAC) cells in a dose- dependent manner (p < 0.05)

  • These results suggested that HG condition, at a concentration of 25 mM, significantly enhanced the proliferation of PDAC cells in vitro (p < 0.05)

  • DHA effectively inhibited the expression of phosphorylated Rb (p-Rb), cyclin D1, cyclin E, cyclin A, E2F1 and c-Myc proteins. These results suggested that DHA could act as an effective agent to suppress cell proliferation through downregulation of cell cycle regulatory proteins upon the stimulation of HG in human HPAF-II cells

Read more

Summary

Introduction

Pancreatic cancer is one of the leading causes of cancer mortality in many countries [1]. Around 85% of pancreatic cancers belong to the adenocarcinoma subtype [2]. Antioxidants 2021, 10, 1721 with pancreatic ductal adenocarcinoma (PDAC) have a five-year survival rate of only. More than 90% of PDAC patients have mutationally activated Kras oncogene [3]. The reprogrammed metabolism and aberrant nucleotide synthesis were driven by Kras mutation in PDAC cells [4,5]. PDAC cells are dependent on glucose to maintain their metabolisms for proliferation and regulate anti-apoptotic escape [4]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.